Mortality and survival in systemic sclerosis: Systematic review and meta-analysis

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 2, 2014, Pages 208-219

  Rubio Rivas, Manuel ^a   Royo, Cristina ^a   Simeón, Carmen Pilar ^b   Corbella, Xavier ^a   Fonollosa, Vicent ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Mortality; Systemic sclerosis

Indexed keywords

AGE; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CUMULATIVE SURVIVAL; DIFFUSE SUBSET SYSTEMIC SCLEROSIS; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL DISEASE; GENDER; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LUNG DISEASE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RISK ASSESSMENT; RISK FACTOR; SCLERODERMIC RENAL CRISIS; STANDARDIZED MORTALITY RATIO; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; ADULT; COMPLICATION; FEMALE; LUNG DISEASES; MALE; MIDDLE AGED; MORTALITY; TIME;

ADULT; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TIME FACTORS;

EID: 84927553746     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.05.010     Document Type: Article

References (89)

1. Walsh S.J., Fenster J.R. Geographical clustering of mortality from systemic sclerosis in the southeastern United States 1981-90. J Rheumatol 1997, 24:2348-2352.
2. Ioannidis J., Vlachoyiannopoulos P., Haidich A.B., Medsger T.A., Lucas M., Michet C.J., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005, 118:2-10.
3. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
4. Curtin L.R., Klein R.J. Direct standardization (age-adjusted death rates). Statistical notes; no.6. Hyattsville, Maryland: National center for Health Statistics. 1995, 6:1-10.
5. Elhai M., Meune C., Avouac J., Kahan A., Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012, 51:1017-1026.
6. Toledano E., Candelas G., Rosales Z., Martínez Prada C., León L., Abásolo L., et al. A meta-analysis of mortality in rheumatic diseases. Reumatol Clin 2012, 8:334-341.
7. Komócsi A., Vorobcsuk A., Faludi R., Pintér T., Lenkey Z., Korlto G., et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology 2012, 51:1027-1036.
8. Tuffanelli D.L., Winkelmann R.K. Systemic scleroderma. A clinical study of 727 cases. Arch Dermatol 1961, 84:359-371.
9. Farmer R.G., Gifford R.W., Hines E.A. Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma: a study of 271 cases. Circulation 1960, 21:1088-1095.
10. Masi A.T., D'Angelo W.A. Epidemiology of fatal systemic sclerosis (diffuse scleroderma). A 15-year survey in Baltimore. Ann Intern Med 1967, 66:870-883.
11. Medsger T.A., Masi A.T. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 1971, 74:714-721.
12. Bennet R., Bluestone R., Holt P.J.L. Survival in scleroderma. Ann Rheum Dis 1971, 30:581-588.
13. Medsger T.A., Masi A.T. The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. J Chron Dis 1978, 31:73-85.
14. Barnett A.J. Scleroderma (progressive systemic sclerosis): progress and course based on a personal series of 118 cases. Med J Aust 1978, 2:129-134.
15. Zarafonetis C., Dabich L., Negri D., Skovronski J.J., DeVol E.B., Wolfe R. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. J Clin Epidemiol 1988, 41:93-205.
16. Medsger T.A., Masi A.T., Rodnan G.P. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971, 75:369-376.
17. Medsger T.A., Masi A.T. Survival with scleroderma. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chron Dis 1973, 26:647-660.
18. Rowell N.R. The prognosis of systemic sclerosis. Br J Dermatol 1976, 95:57-60.
19. Barnett A.J., Miller M.H., Littlejohn G.O. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): The value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988, 15:276-283.
20. Gouet D., Azais I., Marechaud R., Alcalay M., Barriere H., Bontoux D. Pronostic de la sclérodermie generalise. Étude retrospective de 78 observations. Rev Med Interne 1986, 7:233-241.
21. Giordano M., Valentini G., Migliaresi S., Picillo U., Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986, 13:911-916.
22. Altman R.D., Medsger T.A., Bloch D.A., Michel B.A. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991, 34:403-413.
23. Eason R.J., Tan P.L., Gow P.J. Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust N Z J Med 1981, 11:657-662.
24. Wynn J., Fineberg N., Matzer L., Cortada X., Armstrong W., Dillon J.C., et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985, 110:123-127.
25. Silman A.J. Mortality from scleroderma in England and Wales 1968-1985. Ann Rheum Dis 1991, 50:95-96.
26. Peters-Golden M., Wise R.A., Hochberg M.C., Stevens M.B., Wigley F.M. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984, 77:1027-1033.
27. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G. Systemic sclerosis. Demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine 2002, 81:139-153.
28. Lally E.V., Jiménez S.A., Kaplan S.R. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 1988, 18:1-13.
29. Jacobsen S., Ullman S., Shen G.Q., Wiik A., Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001, 28:2454-2459.
30. Jacobsen S., Halberg P., Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998, 37:750-755.
31. Ferri C., Bernini L., Cecchetti R., Latorraca A., Marotta G., Pasero G., et al. Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol 1991, 18:1826-1832.
32. Kuwana M., Kaburaki J., Okano Y., Tojo T., Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994, 37:75-83.
33. Englert H., Small-McMahon J., Davis K., O'Connor H., Chambers P., Brooks P. Systemic sclerosis prevalence and mortality in Sydney 1974-88. Aust N Z J Med 1999, 29:42-50.
34. Geirsson A.J., Steinsson K., Gudmundsson S., Sigurdsson V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis 1994, 53:502-505.
35. Steen V.D., Powell D.L., Medsger T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31:196-203.
36. Abu-Shakra M., Lee P. Mortality in systemic sclerosis. A comparison with the general population. J Rheumatol 1995, 22:2100-2102.
37. Kaburaki J., Lee C.C., Kuwana M., Tojo T., Ikeda Y., Takano M., et al. Initial predictors of survival in systemic sclerosis. Keio J Med 1992, 41:141-145.
38. Lee P., Langevitz P., Alderdice C.A., Aubrey M., Baer P.A., Baron M., et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992, 82:139-148.
39. Nishioka K., Katayama I., Kondo H., Shinkai H., Ueki H., Tamaki K., et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis. J Dermatol 1996, 23:677-682.
40. Simeón C.P., Armadans L., Fonollosa V., Vilardell M., Candell J., Tolosa C., et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997, 56:723-728.
41. Bryan C., Knight C., Black C.M., Silman J. Prediction of five-year survival following presentation with scleroderma. Arthritis Rheum 1999, 42:2660-2665.
42. Simeón C.P., Armadans L., Fonollosa V., Solans R., Selva A., Villar M., et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003, 42:71-75.
43. Bulpitt K.J., Clements P.J., Lachenbruch P.A., Paulus H.E., Peter J.B., Agopian M.S., et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993, 118:602-609.
44. Czirják L., Nagy Z., Szegedi G. Survival analysis of 118 patients with systemic sclerosis. J Intern Med 1993, 234:335-337.
45. Bryan C., Howard Y., Brennan P., Black C., Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheum 1996, 35:1122-1126.
46. Nagy Z., Czirják L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997, 16:454-460.
47. Geirsson A.J., Wollheim F.A., Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001, 60:1117-1122.
48. Krishnan E., Furst D.E. Systemic sclerosis mortality in the United States: 1979-98. Eur J Epidemiol 2005, 20:855-861.
49. Hesselstrand R., Scheja A., Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998, 57:682-686.
50. Bond C., Pile K.D., McNeil J.D., Ahern M.J., Smith M.D., Cleland L.G., et al. South Australian scleroderma register: analysis of deceased patients. Pathology 1998, 30:386-390.
51. Vlachoyiannopoulos P.G., Dafni U.G., Pakas I., Spyropoulou-Vlachou M., Stavropoulos-Giokas C., Moutsopoulos H.M. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000, 59:359-367.
52. Kernéis S., Boëlle P., Grais R.F., Pavillon G., Jougla E., Flahault A., et al. Mortality trends in systemic sclerosis in France and USA 1980-1998: an age period-cohort analysis. Eur J Epidemiol 2010, 25:55-61.
53. Kim J., Park S.K., Moon K.W., Lee E.Y., Lee Y.J., Song Y.W., et al. The prognostic factors of systemic sclerosis for survival among Koreans. Clin Rheumatol 2010, 29:297-302.
54. Mayes M.D., Lacey J.V., Beebe-Dimmer J., Gillespie B.W., Cooper B., Laing T.J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255.
55. Hashimoto A., Tejima S., Tono T., Suzuki M., Tanaka S., Matsui T., et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 2011, 38:1-9.
56. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich E., Goulet J.R., et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002, 81:154-167.
57. Pérez-Bocanegra C., Solans-Laqué R., Simeón-Aznar C.P., Campillo M., Fonollosa V., Vilardell M. Age-related survival and clinical features in systemic sclerosis patients older or younger than 65 at diagnosis. Rheumatology 2010, 49:1112-1117.
58. Alamanos Y., Tsifetaki N., Voulgari P.V., Siozos C., Tsamandouraki K., Alexiou G.A., et al. Epidemiology of systemic sclerosis in Northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005, 34:714-720.
59. Nihtyanova S.I., Tang E.C., Coghlan J.G., Wells A.U., Black C.M. Improved survival in systemic sclerosis is asociated with better ascertaiment of internal organ disease: a retrospective cohort study. Q J Med 2010, 103:109-115.
60. Joven B.E., Almodovar R., Carmona L., Carreira P.E. Survival, causes of death and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single University Hospital. Semin Arthritis Rheum 2010, 39:285-293.
61. Ruangjutipopan S., Kasitanon N., Louthrenoo W., Sukitawut W., Wichainun R. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai 2002, 85:1204-1209.
62. Czirják L., Kumánovics G., Varjú C., Nagy Z., Pákozdi A., Szekanecz Z., et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008, 67:59-63.
63. Derk C.T., Huaman G., Littlejohn J., Otieno F., Jiménez S. Predictors of early mortality in systemic sclerosis: a case-control study comparing early versus late mortality in systemic sclerosis. Rheumatol Int 2012, 32:3841-3844.
64. Arias-Núñez M.C., Llorca J., Vázquez-Rodríguez T.R., Gómez-Acebo I., Miranda-Filloy J.A., Martin J., et al. Systemic sclerosis in northwestern Spain. Medicine 2008, 5:272-280.
65. Roberts-Thomson P.J., Walker J.G., Lu T.Y., Esterman A., Hakendorf P., Smith M.D. Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation. Intern Med J 2006, 36:489-497.
66. Alba M.A., Velasco C., Simeón C.P., Fonollosa V., Trapiella L., Egurbide M.V., et al. Differences in clinical presentation and outcome between early versus late onset systemic sclerosis: analysis of 1037 patients. Medicine 2014, 93:73-81. [Epub ahead of print].
67. Al-Dhaher F.F., Pope J.E., Ouimet J.M. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010, 39:269-277.
68. Sampaio-Barros P.D., Bortoluzzo A.B., Marangoni R.G., Rocha L.F., Del Rio A.P.T., Samara A.M., et al. Survival, causes of death and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012, 39:1971-1978.
69. Hissaria P., Lester S., Hakendorf P., Woodman R., Patterson K., Hill C., et al. Survival in scleroderma: results from the population-based South Australian Register. Intern Med J 2011, 41:381-390.
70. Mendoza F., Derk C.T. Systemic sclerosis mortality in the United States. J Clin Rheumatol 2007, 13:187-192.
71. Fransen J., Popa-Diaconu D., Hesselstrand R. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in Eustar centres. Ann Rheum Dis 2011, 70:1788-1792.
72. Assassi S., Junco D., Sutter K., McNearney T., Reveille J.D., Karnavas A., et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 2009, 61:1403-1411.
73. Mok C.C., Kwok C.L., Ho L.Y., Chan P.T., Yip S.F. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011, 63:1182-1189.
74. Hoffmann-Vold A., Molberg O., Midtvedt O., Garen T., Gran J.T. Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol 2013, 40:1127-1133.
75. Vettori S., Cuomo G., Abignano G., Iudici M., Valentini G. Survival and death causes in 251 systemic sclerosis patients from a single Italian centre. Reumatismo 2010, 62:202-209.
76. Hachulla E., Carpentier P., Gressin V., Diot E., Allanore Y., Sibilia J., et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology 2009, 48:304-308.
77. Strickland G., Pauling J., Cavill C., Shaddick G., McHugh N. Mortality in systemic sclerosis-a single centre study from the UK. Clin Rheumatol 2013, 32:1533-1539.
78. Kuo C.F., See L.C., Yu K.H., Chou I.J., Tseng W.Y., Chang H.C., et al. Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2011, 40:373-378.
79. Tyndall A.J., Bannert B., Vonk M., Airò P., Cozzi F., Carreira P.E., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809-1815.
80. LeRoy E.C., Black C., Fleischmajer R. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
81. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
82. O'Leary P.A., Waissman M. Acrosclerosis. Arch Dermatol Syph 1943, 47:382-397.
83. Tuffanelli D.L., Winkelmann R.K. Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 1962, 57:198.
84. Wells G, Shea B, O'Connell D. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. http://www.ohri.ca/programs/clinical_epidemiology%20/oxford.htm.
85. Iglewicz P.J., Hoaglin D.C. How to detect and handle outliers 1993, American Society for Quality Control, Milwaukee, WI.
86. Kahn H.A., Sempos C.T. Statistical methods in epidemiology 1989, 76-79. Oxford University Press, New York.
87. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 2003, 327:557-560.
88. Begg C.B., Berlin J.A. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989, 81:107-115.
89. Onishi A., Sugiyama D., Kumagai S. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013, 65:1913-1921.